Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study
Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA)...
Drug
Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...
Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer
Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...
Bio-Thera Solutions Gets NMPA Green Light for PD-1 Inhibitor BAT1308 in Endometrial Cancer
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Sanofi’s Rezurock Secures Marketing Approval in China for Chronic Graft-vs-Host Disease
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that its drug Rezurock (belumosudil), the world’s...
InnoCare’s TYK2 Inhibitor ICP-332 Shows Positive Results in Atopic Dermatitis Phase II Study
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and...
MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma
The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck,...
3D Medicines Initiates Phase III Trial for Envafolimab in NSCLC Patient
3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the enrollment of the first...
Sino Biopharmaceutical Submits Market Approval Application for Recombinant Coagulation Factor VIIa
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Lepu Biotechnology’s Pancreatic Cancer Drug Earns Orphan Drug Status from FDA
Lepu Biotechnology Co., Ltd (HKG: 2157), a Chinese pharmaceutical company, has announced that it has...
AbbVie and Genmab’s Epcoritamab Shows Promising Results in Follicular Lymphoma Study
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have presented Phase I/II clinical data for their...
Amgen’s Tarlatamab Receives FDA Priority Review for Advanced Small Cell Lung Cancer Treatment
The US Food and Drug Administration (FDA) has granted priority review status to Amgen (NASDAQ:...
Eisai and BioArctic Set December Launch for Alzheimer’s Drug Leqembi in Japan
Eisai (TYO: 4523) and BioArctic (STO: BIOA-B) have announced the launch of Leqembi (lecanemab) in...
Abbisko Therapeutics’ Pimicotinib Earns FDA Fast-Track Status for TGCT Treatment
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology firm, has announced that its colony...
BMS Presents Promising Golcadomide Trial Results for Non-Hodgkin Lymphomas
Bristol Myers Squibb (BMS; NYSE: BMY) has presented results from Phase I and Phase I/II...
J&J’s Carvykti Demonstrates Extended Time to Symptom Worsening in Multiple Myeloma Patients
Johnson & Johnson (J&J; NYSE: JNJ) has released data from a Phase III study showing...
Dizal Pharmaceutical Presents Positive Trial Data for Golidocitinib at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd, (SHA: 688192), a spin-off from AstraZeneca (AZ, NASDAQ: AZN) China...
China Medical System Gets NMPA Green Light for Phase III Vitiligo Study with Ruxolitinib Cream
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...
CARsgen Therapeutics Halts Clinical Studies for Three CAR-T Therapies in the US Following FDA Request
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the US Food and Drug...